Broad-spectrum mono- and combinational drug therapies for global viral pandemic preparedness
Ianevski, A.; Yao, R.; Simonsen, R. M.; Myhre, V.; Ravlo, E.; Kaynova, G. D.; Zusinaite, E.; White, J. M.; Pan, Q.; Polyak, S. J.; Oksenych, V.; Windisch, M. P.; Lastauskiene, E.; Vitkauskiene, A.; Matukevicius, A.; Tenson, T.; Bjoras, M.; Kainov, D. E.
Show abstract
Broadly effective antiviral therapies must be developed to be ready for clinical trials, which should begin soon after the emergence of new life-threatening viruses. Here, we pave the way towards this goal by analyzing conserved druggable virus-host interactions, mechanisms of action and immunomodulatory properties of broad-spectrum antivirals (BSAs), routes of BSA delivery, and BSA interactions with other antivirals. Based on the analysis we developed scoring systems, which allowed us to predict novel BSAs and BSA-containing drug combinations (BCCs). Thus, we have developed a new strategy to broaden the spectrum of BSA indications and predict novel mono-and combinational therapies that can help better prepare for imminent future viral outbreaks. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=141 SRC="FIGDIR/small/476444v2_ufig1.gif" ALT="Figure 1"> View larger version (47K): org.highwire.dtl.DTLVardef@7fee8dorg.highwire.dtl.DTLVardef@1069131org.highwire.dtl.DTLVardef@2632bforg.highwire.dtl.DTLVardef@1cdcbf0_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 95%
- Identification of novel Ebola virus inhibitors using biologically contained virus 94%
- Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo 94%
Similar papers in this journal
- Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro 94%
- Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity 94%
- Selective estrogen receptor modulators limit alphavirus infection by targeting the viral capping enzyme nsP1 93%
Similar papers in this journal
Similar papers in this journal
- SynToxProfiler: an approach for top drug combination selection based on integrated profiling of synergy, toxicity and efficacy 95%
- Protein Domain-Based Prediction of Compound-Target Interactions and Experimental Validation on LIM Kinases 93%
- Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.